Picking up these five top stocks for portfolios this month could prove profit-friendly.
A recent tumble in marijuana stocks may offer a great buy opportunity.
One of the marijuana industry’s pioneers was just ousted from Canopy Growth. What comes next?
Pot packaging revenue is skyrocketing thanks to marijuana legalization.
Why you ought to consider buying these well-known companies.
These foreign stocks could be great additions to portfolios.
This beer, wine, and spirits leader is benefiting from selling off underperforming brands.
These could be among the fastest-growing shares over that time frame.
It can help high-income earners save a lot of money in retirement.
Following European approval earlier this month, bluebird bio announced its beta-thalassemia gene therapy will launch with a sky-high price tag.
Surging sales were shy of industry watchers' expectations, but management's guidance shows it's unfazed by a quarterly slowdown.
Updated data from a late-stage trial of voxelotor fell shy of investors' expectations.
Here are this year's winners and losers following the Super Bowl of biotech conferences.
Here's why it could be the perfect time to add these income stocks to your portfolio.
Investors will get additional insight into a potential new treatment for sickle cell disease on Friday.
These big-cap technology companies could be bargains worth buying.
Shock waves from a competitor's stumble sent the clinical-stage biotech's shares reeling.
European regulators have signed off on the biotech's revolutionary gene therapy for beta-thalassemia.
These top healthcare stocks could be worth adding to portfolios if the market sells off sharply.
The sky-high price of this revolutionary new gene therapy may not be as crazy as it seems.